Singapore: Qiagen has acquired US-based Ingenuity Systems, a leading provider of software solutions to efficiently and accurately analyze and interpret genomic data. New technologies such as next-generation sequencing (NGS) are now generating more data in a single year than was created in all prior history, making the analysis and interpretation of this extensive and very complex biological data a critical success factor.
The foundation of Ingenuity's product portfolio is the Ingenuity Knowledge Base, which is built on algorithms that pair all human gene variants with biological interpretations based on known outcomes and findings.
These pairings are collected and reviewed by experts (curated) in a standardized way from a wide range of sources including clinical and scientific publications with the support of advanced technology and refined processes. This process and the associated learning algorithms translate sourced data into interoperable and linkable collections of relevant information.
Dr Peer M Schatz, CEO, Qiagen, said that, "We are looking forward to expanding the seamless integration of leading biomedical information solutions into our full range of molecular testing solutions, thereby providing our customers a unique experience from sample to interpreted result and recommendations for next steps. Integration of Ingenuity's solutions into a powerful, full-range ecosystem of Qiagen molecular testing solutions, such as PCR and next-generation sequencing, promises to offer significant value to Qiagen customers and shareholders."
Dr Jake Leschly , president and CEO, Ingenuity Systems, said that, "The Ingenuity mission from day one has been to accelerate scientific discovery and enhance clinical decision-making through a rich understanding of biological systems. As part of Qiagen, we will offer our biological knowledge content and software in the context of a best-in-class ecosystem of molecular testing solutions and to a greatly expanded range of customers around the world."
